Einfluss des IDO2-Blockers D-1MT auf die IDO-Aktivität humaner Tumoren und dendritischer Zellen

S. Löb, P. Terness, D. Zieker, R. Schäfer, B. Brücher, H.G. Rammensee & A. Königsrainer
Introduction: Clinical phase-I-trials with cancer patients have been started with the aim of inducing tumor immunity by blocking the immunosuppressive action of indoleamine-2,3-dioxygenase (IDO) with the IDO2-inhibitor dextro-1-methyl-tryptophan (D-1MT). In this study we analyzed IDO2- and IDO1-expression[for full text, please go to the a.m. URL]